Olema Pharmaceuticals, Inc. Earnings Per Share Disclosure
Net Loss Per Common Share
Basic and diluted net loss per common share was calculated as follows (in thousands, except share and per share amounts):
|
|
Years Ended December 31, |
|
|||||||
|
|
2024 |
|
|
2023 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
||
Net loss |
|
$ |
|
(129,474 |
) |
|
$ |
|
(96,655 |
) |
Denominator: |
|
|
|
|
|
|
|
|
||
Weighted average shares used to compute net loss per share, basic and diluted* |
|
|
|
58,743,522 |
|
|
|
|
45,247,098 |
|
Net loss per share, basic and diluted |
|
$ |
|
(2.20 |
) |
|
$ |
|
(2.14 |
) |
|
|
|
|
|
|
|
|
|
||
* reflects the weighted average effect of the pre-funded warrants issued on December 4, 2024 for basic and diluted net loss per share. |
|
|||||||||
The potentially dilutive shares that were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented are as follows:
|
|
Years Ended December 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Options to purchase common stock |
|
|
11,353,057 |
|
|
|
8,670,742 |
|
Unvested performance-based restricted stock units |
|
|
— |
|
|
|
403,000 |
|
Unvested restricted common stock |
|
|
— |
|
|
|
80,703 |
|
Employee stock purchase plan contingently issuable |
|
|
— |
|
|
|
13,988 |
|
|
|
|
11,353,057 |
|
|
|
9,168,433 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 18, 2025 | Showing above |
| 2022 | Mar 9, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.